JAK3/STAT5/6 Pathway Alterations Are Associated with Immune Deviation in [[PQ_REPLACE:[math]]]<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mtex t >CD</mml:mtext><mml:msup><mml:mn mathvariant="bold">8</mml:mn><mml:mtext>+</mml:mtext></mml:msup></ m ml:mrow></mml:math> T Cells in Renal Cell Carcinoma Patients

To investigate the molecular mechanisms underlying altered T cell response in renal cell carcinoma (RCC) patients, we compared autologous and allogeneic [[PQ_REPLACE:[math]]]CD8+ T cell responses against RCC line from RCC patients and their HLA-matched donors, using mixed lymphocyte/tumor cell cultures (MLTCs). In addition, we analyzed the expression of molecules associated with cell cycle regulation. Autologous MLTC responder [[PQ_REPLACE:[math]]]CD8+ T cells showed cytotoxic activity against RCC cell lines; however the analysis of the distribution of [[PQ_REPLACE:[math]]]CD8+ T-cell subsets revealed that allogenic counterparts mediate superior antitumor efficacy. In RCC patients, a decreased proliferative response to tumor, associated with defects in JAK3/STAT5/6 expression that led to increased p27KIP1 expression and alterations in the cell cycle, was observed. These data define a molecular pathway involved in cell cycle regulation that is associated with the dysfunction of tumor-specific [[PQ_REPLACE:[math]]]CD8+ effector cells. If validated, this may define a therapeutic target in the setting of patients with RCC.